5 hours Ago By ABMN Staff
StockNews.com upgraded shares of Alnylam Pharmaceuticals ( NASDAQ:ALNY – Free Report ) from a hold rating to a buy rating in a research note published on Wednesday. Several other research analysts also recently commented on the stock.
JPMorgan Chase & Co. raised their price target on shares of Alnylam Pharmaceuticals from $248.00 to $280.
00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $220.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th.
Bank of America increased their price objective on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a “buy” rating in a research note on Monday, October 14th.
William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a research report on Tuesday, November 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $400.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th.
One equities research analyst has rated the stock with a sell rating, five have given a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $298.
09. View Our Latest Research Report on Alnylam Pharmaceuticals Alnylam Pharmaceuticals Trading Up 2.8 % Alnylam Pharmaceuticals ( NASDAQ:ALNY – Get Free Report ) last announced its quarterly earnings data on Thursday, October 31st.
The biopharmaceutical company reported ($0.87) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.
36). The business had revenue of $500.90 million during the quarter, compared to the consensus estimate of $532.
91 million. During the same quarter in the previous year, the business earned $1.15 earnings per share.
The firm’s revenue was down 33.3% compared to the same quarter last year. On average, equities analysts forecast that Alnylam Pharmaceuticals will post -2.
21 EPS for the current year. Insider Buying and Selling at Alnylam Pharmaceuticals In other news, CMO Pushkal Garg sold 1,682 shares of the company’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.
98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.
86. This represents a 8.79 % decrease in their ownership of the stock.
The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink . Also, CEO Yvonne Greenstreet sold 5,219 shares of the stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.
98, for a total transaction of $1,309,864.62. Following the completion of the transaction, the chief executive officer now directly owns 78,880 shares of the company’s stock, valued at $19,797,302.
40. The trade was a 6.21 % decrease in their ownership of the stock.
The disclosure for this sale can be found here . Insiders sold a total of 10,122 shares of company stock worth $2,540,455 over the last three months. Corporate insiders own 1.
50% of the company’s stock. Institutional Trading of Alnylam Pharmaceuticals Several large investors have recently bought and sold shares of ALNY. Geode Capital Management LLC grew its holdings in shares of Alnylam Pharmaceuticals by 3.
2% during the third quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock valued at $589,209,000 after buying an additional 66,928 shares during the last quarter. TD Asset Management Inc lifted its position in Alnylam Pharmaceuticals by 6.
0% during the 2nd quarter. TD Asset Management Inc now owns 489,940 shares of the biopharmaceutical company’s stock worth $119,055,000 after acquiring an additional 27,592 shares during the period. Charles Schwab Investment Management Inc.
grew its stake in Alnylam Pharmaceuticals by 3.6% during the 3rd quarter. Charles Schwab Investment Management Inc.
now owns 487,348 shares of the biopharmaceutical company’s stock valued at $134,035,000 after purchasing an additional 16,756 shares during the last quarter. Avoro Capital Advisors LLC grew its stake in Alnylam Pharmaceuticals by 33.3% during the 2nd quarter.
Avoro Capital Advisors LLC now owns 400,000 shares of the biopharmaceutical company’s stock valued at $97,200,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Swiss National Bank increased its holdings in shares of Alnylam Pharmaceuticals by 0.3% in the third quarter.
Swiss National Bank now owns 375,400 shares of the biopharmaceutical company’s stock valued at $103,246,000 after purchasing an additional 1,000 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.
Alnylam Pharmaceuticals Company Profile ( Get Free Report ) Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. Featured Stories Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
